CAS 349085-82-1: 4-Methoxy-N-(2,4,6-triMethylphenyl)benzenesulfonaMide

GSK137647A

GSK 137647A is an investigational pharmaceutical compound, which is a selective agonist sourced from GlaxoSmithKline's research laboratories. Its mode of action involves the stimulation of beta-3 adrenergic receptors, which are primarily located in adipose tissue and, notably, in cardiac tissue. This receptor activation leads to increased lipolysis and thermogenesis in adipose tissues, while in the cardiac tissue, it modulates heart function. The primary uses and applications of GSK 137647A are centered around cardiovascular research, particularly in exploring new therapeutic avenues for heart failure and related conditions. By understanding the role of beta-3 adrenergic receptor activation, scientists aim to elucidate potential mechanisms for improving cardiac output and overall heart function. This compound is pivotal in preclinical studies to assess its efficacy and potential side effects, serving as a critical tool in the development of future cardiovascular therapies.

GSK137647A (GSK 137647) is a selective FFA4 agonist.

Gsk137647A